सत्यमेव जयते

Government of India
Central Drugs Standard Control Organisation (Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File. No. BIO/CT/25/000147 Dated 11.05.2026

To

M/s. Hetero Biopharma Limited,
H.No. 8-3-166/1 & 2, 105 To 108, 1st Floor, G Block, East Wing,
Challa Estates, Erragadda, Hyderabad (India) - 500018

Subject: Application for grant of permission to conduct a phase I/III study titled - "A Prospective, Randomized, Multicenter, Double Blind, Active Controlled, Parallel Group Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of Hetero-Pertuzumab (Hetero Biopharma Ltd, India) with Reference Medicinal Product (Pertuzumab, Genentech Inc.,) in Combination with Trastuzumab and Docetaxel in Previously Untreated Patients with Human Epidermal Growth Factor Receptor (HER) – 2 Positive Metastatic Breast Cancer" vide Protocol No.: **HCR/III/PERMBC/08/2025, Version No.: 1.0, dated 29 August 2025** – regarding.

Ref. No.:

1. Your Application No. **BIO/CT04/FF/2025/52309 dated 27.09.2025**.
2. Recommendation of SEC (Oncology) meeting dated 21.01.2026

Sir,

With reference to your application No. BIO/CT04/FF/2025/52309 dated 27.09.2025, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

(I) All Principal Investigators (PIs) shall be Medical Oncologists.
(II) Day care facilities shall not be used as clinical trial sites.
(III) Clinical trial sites shall be geographically distributed.
(IV) Number of patients shall be proportionate across all clinical trial sites.
(V) Post-trial access of the study drug shall be provided to the subjects till disease progression.
(VI) You are required to submit the Clinical study report after completion of study.
(VII) CT-21 application shall be made by a person who manufactures new drug in the form of active pharmaceutical ingredient or pharmaceutical formulation for sale or distribution.
(VIII) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8.
(IX) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(X) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(XI) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(XII) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.

(XIII) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(XIV) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(XV) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.

(XVI) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.

(XVII) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.

(XVIII) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.

(XIX) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.

(XX) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.

(XXI) The laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.

(XXII) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective,

design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.

(XXIII) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(XXIV) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2026.05.11 14:39:13 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

CENTRAL DRUGS STANDARD CONTROL ORGANISATION
CDSCO CDSCO
सत्यमेव जयते
MINISTRY OF HEALTH, GOVERNMENT OF INDIA